Coagulation monitoring and management of bleeding complications in treatment using new peroral anticoagulants from a haematologist perspective
2013
Abstract
At present we already have 3 new oral anticoagulants (NOAC) - dabigatran etexilate, rivaroxaban and apixaban – at our disposal. Their indications are short-term (maximum of 35 days) prevention of thromboembolic complications after orthopaedic hip or knee joint replacement surgery and long term prevention of cardioembolic stroke when atrial fibrillation is present.
Rivaroxaban is still indicated for treatment of venous thrombosis and pulmonary embolism This article gives an overview of the possibilities of laboratory coagulation monitoring and of the recommendations for management of bleeding complications.